Latest Industrial Growth News

Audinate’s FY25 was a year of strategic transition marked by shipment of one million Dante devices, launch of a cloud-based management platform, and acquisition of Iris Studio to bolster AI-driven video capabilities. Despite revenue headwinds, the company is poised for growth in FY26 with strong gross profit momentum and a robust balance sheet.

Audinate reported a 33% revenue decline in FY25 due to OEM inventory adjustments but boosted gross margins to 82.1% through a software shift and completed the strategic Iris acquisition, setting the stage for growth in FY26.

Mirvac Group reported a solid FY25 with $736 million EBIT and expanded its Build-to-Rent portfolio, while guiding for EPS growth in FY26 amid a supportive market backdrop.

Tetratherix has landed a $3.3 million Australian Government grant to co-fund a $7.4 million project expanding its synthetic polymer production and supporting its US market entry in 2026.

Dexus Industria REIT reported robust FY25 financials, marked by resilient income growth and strategic portfolio repositioning to 100% industrial assets. Key acquisitions and divestments, alongside a $230 million development pipeline, position the REIT for sustained growth.

Iondrive Limited has won a $3.9 million government grant to advance its innovative urban mining technology, accelerating the construction of a pilot plant focused on critical minerals recovery from lithium-ion batteries.

xReality Group has secured a $2.1 million grant from the Australian Government to fast-track AI enhancements in its Operator XR tactical training platform, aiming to solidify its leadership in law enforcement and defense training worldwide.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Vitrafy Life Sciences reported strong FY25 progress with 75% sales growth, advanced cryopreservation technology development, and a robust cash position. The company outlines a clear commercialisation roadmap for FY26, including product launches and expanded U.S. operations.

Vitrafy Life Sciences reported a $32.7 million loss for FY25, driven by investments in its next-generation cryopreservation platform following a $35 million IPO and a $4.8 million government grant. The company is progressing commercialization efforts with key partnerships in human and animal health.

Latrobe Magnesium secures EPA licence extension and prepares to start magnesium oxide production in August, while pursuing a significant legal counterclaim and advancing commercial plant plans.

Garda Property Group’s FY25 results reveal a strategic pivot with significant asset sales and a sharp reduction in gearing, setting the stage for an 11% rise in distributions in FY26.